TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012

Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.

Susan Branford et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.